Table 3.
Neuromuscular Blocking Agent dose by last documented Train-of-Four prior to reversal and Body Mass Index category
| Total dose of NMB (ED 95 equivalent)a | Last dose of NMB (ED 95 equivalent)a | Time between last NMB & first neostigmine dose (minutes)b | Time between first neostigmine dose & extubation (minutes)b | |
|---|---|---|---|---|
| Median [IQR] | Median [IQR] | Median [IQR] | Median [IQR] | |
| Last TOF prior to reversal | ||||
| 0/4 | 3.5 [2.4, 5.2] | 1.3 [0.7, 2.4] | 52.0 [36.0, 80.3] | 12.0 [8.0, 18.0] |
| 1/4 | 4.0 [2.8, 5.8] | 0.8 [0.5, 1.7] | 42.0 [29.0, 59.0] | 12.5 [8.0, 19.0] |
| 2/4 | 4.0 [2.8, 5.9] | 0.7 [0.4, 1.4] | 43.6 [31.0, 61.0] | 12.8 [8.0, 18.9] |
| 3/4 | 4.0 [2.7, 5.8] | 0.7 [0.4, 1.5] | 49.0 [35.0, 68.0] | 12.4 [8.0, 19.0] |
| 4/4 | 3.5 [2.5, 5.3] | 0.8 [0.5, 1.8] | 65.0 [44.0, 95.0] | 12.7 [8.0, 19.0] |
| Undocumented | 3.3 [2.2, 5.1] | 0.7 [0.4, 1.8] | 43.0 [24.0, 76.0] | 12.0 [7.3, 18.0] |
| WHO BMI categoryc | ||||
| Underweight | 2.9 [2.0, 4.4] | 0.8 [0.5, 1.6] | 57.4 [39.0, 86.4] | 13.8 [9.0, 21.0] |
| Normal Weight | 3.3 [2.2, 4.9] | 0.8 [0.4, 1.8] | 58.0 [39.0, 86.0] | 13.0 [8.0, 19.0] |
| Overweight | 3.6 [2.5, 6.3] | 0.7 [0.4, 1.8] | 58.9 [39.0, 87.9] | 12.1 [8.0, 19.0] |
| Class I Obese | 3.8 [2.7, 5.7] | 0.8 [0.5, 1.9] | 59.0 [39.0, 87.5] | 12.1 [8.0, 19.0] |
| Class II Obese | 4.0 [2.7, 5.9] | 0.8 [0.5, 2.0] | 58.5 [39.1, 88.1] | 12.3 [8.0, 19.0] |
| Class III Obese | 4.2 [2.9, 6.3] | 0.8 [0.5, 1.9] | 57.0 [38.0, 85.0] | 12.9 [8.0, 19.0] |
ED95 effect dose for which 95 % of the population exhibits the effect, TOF train-of-four, WHO World Health Organization, BMI body mass index
aOnly among patients with IBW between 40 and 250 kg
bOnly among patients receiving neostigmine
cOnly among patients with BMI between 10 and 80